Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

The Well Tolerated VA-Based Regimen Bringing to High Quality of Life Did Not Absolutely Inferior to Intensive Chemotherapy in AML Patients with NPM1 Mutation

Wenbing Duan, Qi Chen, WenJing Yu, Jinsong Jia, Jing Wang, Xiaolu Zhu, Ting Zhao, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Hongxia Shi, Ying-Jun Chang, Yu Wang, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2024) 144 (Supplement 1): 5952.

https://doi.org/10.1182/blood-2024-206400

Published: 2024

Journal Articles

Impact of FLT3-ITD Molecular Characteristics on the Prognosis of Patients with De Novo Acute Myeloid Leukemia

Kainan Zhang, Xiaohang Ma, Xiaoxuan Lu, Guo-rui Ruan, Fangfang Wei, Hao Jiang, Xiao Jun Huang, Xiaosu Zhao

Blood (2024) 144 (Supplement 1): 5940.

https://doi.org/10.1182/blood-2024-201537

Published: 2024

Journal Articles

Sex Differences in Disease Characteristics and Outcome in Adults with Acute Myeloid Leukemia from China

Zongru Li, Lu Yu, Li-Juan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 6121.

https://doi.org/10.1182/blood-2024-211874

Published: 2024

Journal Articles

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia

Lin-Ya Wang, Feifei Tang, Xiao-Jun Huang, Hai-Tao Gao, Qiang Fu, Qian Jiang, Hao Jiang, Yu Wang, Lan-Ping Xu, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 6067.

https://doi.org/10.1182/blood-2024-202795

Published: 2024

Journal Articles

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Lu Yu, Lijuan Hu, Zongru Li, Ting Zhao, Wenbing Duan, Jing Wang, JinSong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, LanPing Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2024-207269

Published: 2024

Journal Articles

Recurrent ASXL1 Mutations Promote Myeloid Malignancies through Unleashed Condensation

Maria Latacz, Yansu Song, Yi Hao, Marta Cykowiak, Julia Kirylczuk, Jing Hu, Bi Shi, Hao Jiang

Blood (2024) 144 (Supplement 1): 42.

https://doi.org/10.1182/blood-2024-204634

Published: 2024

Journal Articles

Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Menglin Li, Yi-Meng Li, Qingyuan Qu, Yuxiu Chen, Jianying Zhou, Mengyu Xiao, Chencong Wang, Qi Chen, Xiaolu Zhu, Yun He, YuanYuan Zhang, Qian Jiang, Hao Jiang, Jin Lu, YingJun Chang, Xiaosu Zhao, Xiangyu Zhao, Xiao Jun Huang, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2024-204777

Published: 2024

Journal Articles

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Zongru Li, Lu Yu, Lijuan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Qiang Fu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 4235.

https://doi.org/10.1182/blood-2024-209768

Published: 2024

Journal Articles

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

Wenbing Duan, Chunkang Chang, Zhiguo Wang, Hongbing Ma, Min Ouyang, Xingli Zhao, Lifan Tu, Guodong Wu, Xunqiang Wang, Xiao Jun Huang, Hao Jiang

Blood (2024) 144 (Supplement 1): 1504.

https://doi.org/10.1182/blood-2024-204972

Published: 2024

Journal Articles

Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy

Zhenkun Wang, Zhi-Wei Zhang, Zhong-Shi Lyu, Tong Xing, Mi Liang, Mengzhu Shen, Chen-Yuan Li, Xin-Yan Zhang, Dan-Dan Chen, Ya-Zhe Wang, Li-Juan Hu, Hao Jiang, Qian Jiang, Yuan Kong, Xiao-Jun Huang

Blood (2024) 144 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2024-201354

Published: 2024

Journal Articles

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Wenbing Duan, Jinsong Jia, Jing Wang, Xiaohong Liu, Lizhong Gong, WenJing Yu, Xiaolu Zhu, Zhao Ting, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Yu Wang, Hongxia Shi, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2023-184769

Published: 2023

Journal Articles

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia

Xiaolu Zhu, Feifei Tang, Wenjing Yu, Xiaosu Zhao, Yazhen Qin, Qian Jiang, Xiao Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2023-180002

Published: 2023

Journal Articles

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Feifei Tang, Wen-Bing Duan, Xiao-Hong Liu, Sheng-Ye Lu, Xiao-Su Zhao, Ya-Zhen Qin, Jin-Song Jia, Jing Wang, Li-Zhong Gong, Qian Jiang, Zhao Ting, Hong-Xia Shi, Ying-Jun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2023-188657

Published: 2023

Journal Articles

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Wen-Jing Yu, Ying Wu, Qi Chen, Xiaolu Zhu, Xu-Ying Pei, Jin-Song Jia, Jing Wang, Xiao-Su Zhao, Ying-Jun Chang, Yue-Yun Lai, Hong-Xia Shi, Guo-Rui Ruan, Ya-Zhen Qin, Xiao-Hong Liu, Xiao Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 1525.

https://doi.org/10.1182/blood-2023-184665

Published: 2023

Journal Articles

The Kinetics of FLT3L during Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia Suggests a Novel Clinical Diagnostic and Treatment Strategy

Wenqing Wang, Yan-lai Tang, Zhen Li, Hao Jiang, Chi-Kong Li, Chun Chen, Yun Chen, Hongman Xue

Blood (2023) 142 (Supplement 1): 5823.

https://doi.org/10.1182/blood-2023-187653

Published: 2023

Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study

Jing Wang, Siqi Li, Hao Jiang, Ying-Jun Chang, Xiao-su Zhao, Jinsong JIA, Xiaolu Zhu, Lizhong Gong, Xiaohong Liu, Wen-Jing Yu, Xiaojun Huang

Blood (2023) 142 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2023-174600

Published: 2023

Journal Articles

A Novel Risk Stratification Model for Cytogenetically Normal Acute Myeloid Leukemia with FLT3-ITD Mutation

Lei-Ming Cao, Ya-Lan Zhou, Ming-Yue Zhao, Li-Xia Liu, Hao Jiang, Ying-Jun Chang, Qian Jiang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Guo-Rui Ruan

Blood (2022) 140 (Supplement 1): 3218–3219.

https://doi.org/10.1182/blood-2022-169126

Published: 2022

Journal Articles

Interferon-α-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia----a Prospective, Single-Arm Study

Xiaohong Liu, Yao Li, Wenjing Yu, Xiaolu Zhu, Jinsong Jia, Lizhong Gong, Xiaosu Zhao, Yingjun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2022) 140 (Supplement 1): 3299–3300.

https://doi.org/10.1182/blood-2022-168422

Published: 2022

Journal Articles

Outcome and Molecular Measurable Residual Disease Monitoring in Adult B-Cell Acute Lymphoblastic Leukemia Patients with MEF2D Fusions

Kai Sun, Wen-Min Chen, Xu Wang, Xiao-Su Zhao, Ling-Di Li, Yue Hao, Jun Wang, Nan Xu, Hao Jiang, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Qian Jiang, Xiao Jun Huang, Ya-Zhen Qin

Blood (2022) 140 (Supplement 1): 11864–11865.

https://doi.org/10.1182/blood-2022-159866

Published: 2022

Journal Articles

Phase I Study of TQB3455, a Selective Inhibitor of IDH2 with Favorable Safety and More Potent Efficacy to IDH2-R172K Mutation, for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Hao Jiang, Xudong Wei, Chunkang Chang, Hongbing Ma, Xuejun Zhang, Xiao-Jun Huang

Blood (2022) 140 (Supplement 1): 9082–9083.

https://doi.org/10.1182/blood-2022-164984

Published: 2022

NARROW

The Well Tolerated VA-Based Regimen Bringing to High Quality of Life Did Not Absolutely Inferior to Intensive Chemotherapy in AML Patients with NPM1 Mutation

Impact of FLT3-ITD Molecular Characteristics on the Prognosis of Patients with De Novo Acute Myeloid Leukemia

Sex Differences in Disease Characteristics and Outcome in Adults with Acute Myeloid Leukemia from China

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Recurrent ASXL1 Mutations Promote Myeloid Malignancies through Unleashed Condensation

Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

The Kinetics of FLT3L during Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia Suggests a Novel Clinical Diagnostic and Treatment Strategy

Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study

A Novel Risk Stratification Model for Cytogenetically Normal Acute Myeloid Leukemia with FLT3-ITD Mutation

Interferon-α-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia----a Prospective, Single-Arm Study

Outcome and Molecular Measurable Residual Disease Monitoring in Adult B-Cell Acute Lymphoblastic Leukemia Patients with MEF2D Fusions

Phase I Study of TQB3455, a Selective Inhibitor of IDH2 with Favorable Safety and More Potent Efficacy to IDH2-R172K Mutation, for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only